Researchers at Tufts University just found two blood markers that can flag Lyme disease before standard tests even turn positive — and that same signal may linger in patients who never fully recover.
Story Snapshot
- Two anti-lipid antibodies — anti-phosphatidic acid and anti-phosphatidylserine — showed up in Lyme patients whose standard tests were still negative
- Anti-phosphatidylserine levels stayed elevated months later in patients with persistent symptoms after treatment
- Researchers say the findings are promising but do not yet support a new clinical test — larger studies are still needed
- This is at least the fifth distinct biomarker proposal since 2019, and none has reached a doctor’s office yet
Why Standard Lyme Tests Miss the Window That Matters Most
A tick bites you. Days pass. You feel off. You get tested. The result comes back negative — but you are infected. This is not a rare edge case. It is the normal experience for many early Lyme patients. Standard blood tests look for antibodies your immune system produces in response to the bacteria. The problem is that your body needs weeks to build enough antibodies to trigger a positive result. By then, the bacteria have had time to spread.
The Centers for Disease Control and Prevention’s own case definition still requires two-tier antibody testing, bacterial culture, or a nucleic acid test to confirm Lyme disease. None of those options reliably catches the infection in its earliest days. That gap has frustrated patients and doctors for decades, and it is exactly the gap the Tufts team is trying to close.
What the Tufts Study Actually Found
The Tufts University School of Medicine team looked at a different class of markers entirely — anti-lipid antibodies, which are antibodies that react to fat-based molecules rather than the bacteria’s proteins. They identified three of these antibodies in Lyme patients. Two of them, anti-phosphatidic acid and anti-phosphatidylserine, were elevated at the time of diagnosis — even in patients who had not yet tested positive on standard Lyme tests. That is the early-detection signal researchers have been hunting for years.
The second finding may matter even more for the roughly 10 to 20 percent of patients who stay sick after treatment. Anti-phosphatidylserine levels remained elevated months later in patients with persistent symptoms. If that pattern holds in larger studies, this marker could help doctors track ongoing disease rather than just guessing based on how a patient feels.
Promising Signal, But Not a Test Yet
The Tufts researchers are direct about what their findings do and do not mean. The study does not yet support a new clinical test. Larger studies are needed to confirm how accurately these markers identify infection and predict long-term symptoms. That is not a dismissal of the work — it is how responsible science communicates early-stage findings. But patients who have spent years fighting for a diagnosis deserve to know this is still a research finding, not a tool their doctor can order tomorrow.
The Hopkins Lyme Center confirms that no single test can definitively confirm or rule out Lyme disease, and that diagnosis remains fundamentally clinical. That reality has not changed. What the Tufts findings offer is a potential new lane of investigation — one that looks at how the body responds to infection at the lipid level rather than waiting for a full antibody response to build.
A Field Crowded With Promising Leads That Stall
Here is the uncomfortable context: researchers have announced promising Lyme biomarkers before. A 2019 study published in Frontiers in Cellular and Infection Microbiology used mass spectrometry and protein microarrays to identify six candidate biomarkers that could potentially enable early detection. A 2023 Nature study pointed to a protein called VlsE as a robust marker for all stages of the disease. A 2024 analysis identified three genes — FCGR1B, MPP1, and HSPA6 — using machine learning on patient data. None of these became a clinical test.
That track record does not mean the Tufts findings will fade the same way. It does mean the path from discovery to a doctor’s office is long, expensive, and uncertain. Regulatory clearance, insurance coverage, and clinical adoption all create friction. Quest Diagnostics chief executive Jim Davis has noted that even well-validated tests like apoB and LP(a) cholesterol markers go underused because commercial payers often do not cover them. A new Lyme test would face the same headwinds.
Why This Research Still Deserves Attention
The anti-lipid antibody angle is genuinely different from prior approaches. Most biomarker research has focused on the bacteria’s proteins or the patient’s genetic response. Targeting fat-based immune signals is a less-traveled path, and the fact that these markers appeared in patients with negative standard tests — and persisted in those with ongoing symptoms — gives researchers two distinct potential uses: earlier diagnosis and treatment monitoring. That dual utility is rare and worth pursuing seriously.
Lyme disease affects an estimated 476,000 Americans each year. Late or missed diagnosis leads to joint damage, neurological problems, and months of lost function. Any tool that catches the infection earlier or tracks treatment response more precisely has real stakes. The Tufts findings are not a solution yet. But they are a credible lead in a field that has needed one for a long time.
Sources:
mindbodygreen.com, frontiersin.org, now.tufts.edu, pmc.ncbi.nlm.nih.gov, frontlinegenomics.com, news.asu.edu
